why choose us

First received: December 9, 2022

Clinical Trial: Irinotecan and Anlotinib for Epithelioid Sarcoma

Study Status: Completed

Recruit Status: Completed

Condition: Objective Response
Overall Survival

Study Type: Interventional


Official Title: A Retrospective Study Investigating the Combination of Irinotecan, Vincristine and Anlotinib for Epithelioid Sarcoma

Brief Summary: Epithelioid sarcoma is a rare soft tissue sarcoma characterized by SMARCB1/INI1 deficiency. Much attention has been paid to the selective EZH2 inhibitor tazemetostat, where other systemic treatments are generally ignored. To explore alternative treatment options, we studied the effects of irinotecan-based chemotherapy in a series of epithelioid sarcoma patients.

Read more